Santorini Scientific has launched a new project to establish a proof-of-concept lab-based tool for the assessment of prevention of cardiac rejection. TVALAB will help develop a novel innovative T-cell therapy approach to manage post-transplant rejection and immunosuppression regime.

Using Santorini Scientific’s experience in advanced in vitro models and our database of rejection markers, a healthy heart model will be established and then challenged to depict a model of rejection. The responses will be monitored by measuring levels of biomarkers, which will bring novel insights into the mechanisms and behaviour of models to different therapies. Developing the model for the heart opens the possibility of screening and accelerating other treatments in the future of the heart and other organs.

After a competitive process, project funding has been awarded by Innovate UK through the Transformative Technologies Programme.

Successful delivery of this project is a stepping stone towards delivering T-cell therapy that can aid in reducing the clinical burden on the NHS whilst also saving thousands of pounds in the process and reducing the dependency on animal testing for researchers.



Innovate UK, part of UK Research and Innovation, is creating a better future by inspiring, involving and investing in businesses developing life-changing innovations. We provide targeted sectors with expertise, facilities and funding to test, demonstrate and evolve their ideas, driving UK productivity and economic growth. Join our network and communities of innovators to realise the potential of your ideas and accelerate business growth. Innovate UK: inspiring business innovation.